BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37633951)

  • 1. USP14 governs CYP2E1 to promote nonalcoholic fatty liver disease through deubiquitination and stabilization of HSP90AA1.
    Wei D; Tian X; Zhu L; Wang H; Sun C
    Cell Death Dis; 2023 Aug; 14(8):566. PubMed ID: 37633951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ma HL; Chen SD; Zheng KI; Yu Y; Wang XX; Tang LJ; Li G; Rios RS; Huang OY; Zheng XY; Xu RA; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2925-2934. PubMed ID: 34031913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1.
    Yang Q; Chen X; Zhang Y; Hu S; Hu F; Huang Y; Ma T; Hu H; Tian H; Tian S; Ji YX; She ZG; Zhang P; Zhang XJ; Hu Y; Yang H; Yuan Y; Li H
    Hepatology; 2021 Dec; 74(6):3018-3036. PubMed ID: 34272738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis.
    Abdelmegeed MA; Banerjee A; Jang S; Yoo SH; Yun JW; Gonzalez FJ; Keshavarzian A; Song BJ
    Free Radic Biol Med; 2013 Dec; 65():1238-1245. PubMed ID: 24064383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
    Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
    Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes.
    Bell LN; Molleston JP; Morton MJ; Klipsch A; Saxena R; Vuppalanchi R; Chalasani N
    J Clin Gastroenterol; 2011 Oct; 45(9):800-7. PubMed ID: 21602702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin Suppresses Ubiquitination via the Deubiquitinating Enzyme Ubiquitin-Specific Protease 14, Independent of Proteasome Activity in H4IIEC3 Hepatocytes.
    Kamoshita K; Ishii KA; Tahira Y; Kikuchi A; Abuduwaili H; Tajima-Shirasaki N; Li Q; Takayama H; Matsumoto K; Takamura T
    J Pharmacol Exp Ther; 2023 Apr; 385(1):5-16. PubMed ID: 36328485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRPV4 activation of endothelial nitric oxide synthase resists nonalcoholic fatty liver disease by blocking CYP2E1-mediated redox toxicity.
    Seth RK; Das S; Dattaroy D; Chandrashekaran V; Alhasson F; Michelotti G; Nagarkatti M; Nagarkatti P; Diehl AM; Bell PD; Liedtke W; Chatterjee S
    Free Radic Biol Med; 2017 Jan; 102():260-273. PubMed ID: 27913210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
    Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
    Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content.
    Bell LN; Temm CJ; Saxena R; Vuppalanchi R; Schauer P; Rabinovitz M; Krasinskas A; Chalasani N; Mattar SG
    Ann Surg; 2010 Jun; 251(6):1041-8. PubMed ID: 20485142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin-specific peptidase 10 ameliorates hepatic steatosis in nonalcoholic steatohepatitis model by restoring autophagic activity.
    Xin SL; Yu YY
    Dig Liver Dis; 2022 Aug; 54(8):1021-1029. PubMed ID: 35288065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHIP(-/-)-Mouse Liver: Adiponectin-AMPK-FOXO-Activation Overrides CYP2E1-Elicited JNK1-Activation, Delaying Onset of NASH: Therapeutic Implications.
    Kim SM; Grenert JP; Patterson C; Correia MA
    Sci Rep; 2016 Jul; 6():29423. PubMed ID: 27406999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purinergic receptor X7 is a key modulator of metabolic oxidative stress-mediated autophagy and inflammation in experimental nonalcoholic steatohepatitis.
    Das S; Seth RK; Kumar A; Kadiiska MB; Michelotti G; Diehl AM; Chatterjee S
    Am J Physiol Gastrointest Liver Physiol; 2013 Dec; 305(12):G950-63. PubMed ID: 24157968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis.
    Zhang L; Zhang Z; Li C; Zhu T; Gao J; Zhou H; Zheng Y; Chang Q; Wang M; Wu J; Ran L; Wu Y; Miao H; Zou X; Liang B
    Cell Mol Gastroenterol Hepatol; 2021; 11(3):697-724. PubMed ID: 33075563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.
    Aubert J; Begriche K; Knockaert L; Robin MA; Fromenty B
    Clin Res Hepatol Gastroenterol; 2011 Oct; 35(10):630-7. PubMed ID: 21664213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.
    Seth RK; Das S; Pourhoseini S; Dattaroy D; Igwe S; Ray JB; Fan D; Michelotti GA; Diehl AM; Chatterjee S
    J Pharmacol Exp Ther; 2015 Jan; 352(1):77-89. PubMed ID: 25347994
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Chen LJ; Lin XX; Guo J; Xu Y; Zhang SX; Chen D; Zhao Q; Xiao J; Lian GH; Peng SF; Guo D; Yang H; Shu Y; Zhou HH; Zhang W; Chen Y
    Int J Biol Sci; 2021; 17(14):3936-3953. PubMed ID: 34671210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.